According to Nova one advisor, the global Drugs of Abuse Testing market size is expected to hit around USD 11.7 billion by 2030 from valued at USD 6.84 billion in 2021 and growing at a CAGR of 7.1% from 2022 to 2030.
Key Takeaways:
Report Scope of the Drugs of Abuse Testing Market
Report Coverage |
Details |
Market Size |
USD 11.7 Billion by 2030 |
Growth Rate |
CAGR of 7.1% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Drug Type, Sample Type, Product , Application End User, and Region, |
Companies Mentioned |
Danaher Corporation, Abbott Laboratories, Quest Diagnostics, Inc., LabCorp, Cordant Health Solutions, Legacy Medical Services, Mayo Clinic Laboratories, DrugScan, LGC Group, Precision Diagnostics |
The imposition of stringent laws mandating alcohol and illicit substance abuse testing is anticipated to drive the market during the forecast period. However, the violation of privacy rights while drug testing is considered a challenge and impedes the adoption of such testing services.
Workplace substance abuse is on the rise despite random tests being conducted by organizations. Commonly abused illicit drugs on the job are cannabis and cocaine. In the workplace, substance abuse might lead to significant loss of productivity, physical injuries, and even fatalities. On the basis of various drug abuse surveys, around 22.5% of people do not admit using alcohol or any illicit drugs during working hours. Around 1 in 10 respondents say that they come prepared to avoid the risk of random tests at the workplace. Therefore, there is a growing need for rapid and frequent drug of abuse testing at the workplace in order to minimize loss of productivity, absenteeism, and healthcare costs. However, with the COVID-19 crisis and subsequent lockdown scenarios throughout the world, people are staying at and working from home, which is expected to reduce the number of substance abuse cases at the workplace.
The National Institute on Drug Abuse (NIDA) has been established as one of the major federal agencies focused on supporting scientific research on drug use disorders and their consequences, thus improving public health. In March 2020, the NIDA issued a Notice of Special Interest (NOSI) highlighting the urgent need for research and data collection and analysis on the risks of COVID-19 infection in people suffering from substance use disorders. This pandemic is a potential threat to individuals who smoke tobacco or marijuana or try vaping, as the infection affects the lungs. This initiative aims at the submission of applications for Competitive Revisions to active grants, targeting research about SARS-CoV-2 infection risks in individuals with substance use disorders, especially with marijuana, nicotine, methamphetamine, and opioids.
Rising Abuse of Prescription Drugs and Increase in Use of Drug Abuse Testing among Private Employers Fuel Market Growth
In recent years, several nations across the globe including the U.S. are experiencing increased cases and death rates due to abuse of prescription drugs or nonmedical utilization of prescription drugs.
The National Institute of Drug Abuse (NIDA) states that approximately 52 million people have utilized prescription drugs for nonmedical reasons for minimum one time in their lifetime. Besides, youth populace from across the globe is seen increasing the use of several pain relievers such as OxyContin and Vicodin, which are considered abused prescription drugs. Due to incorrect prescription and addiction to prescription drugs, there is notable increase in comorbid illnesses among older population. Hence, continuous increase in the abuse of prescription drugs is increasing the sales of drugs of abuse testing products.
People consuming illicit drugs tend to be less productive at work, change their jobs frequently, and they frequently absent at workplaces. These factors can result into increased risks of workplace accidents. As a result, many organizations across the globe are emphasizing on regularly performing drugs of abuse tests. Hence, the demand for drug abuse testing by public and private employers is estimated to increase in the years to come.
North America: Dominant Region for Drugs of Abuse Testing Industry
Europe, North America, Middle East and Africa, Asia Pacific, and Latin America are some of the key regions of the drugs of abuse testing market. Of them, North America is dominant region in the market.
The market is estimated to gain promising sales opportunities in North America in years to come owing to factors such as rise in consumption of illicit drugs and the increase in the availability of insurance plans intended for expensive diagnosis tests in the region.
The nature of the global drugs of abuse testing market is highly fragmented due to existence of several international level players. This scenario represents the highly intense level of competition in the market.
Companies in the drugs of abuse testing market are using different strategies such as acquisitions, collaborations, regulatory approvals, and new products launches. Moreover, several enterprises are increasing investments in R&D projects to develop advanced products. Such initiatives are projected to help in the expansion of the drugs of abuse testing market.
Some of the prominent players in the Drugs of Abuse Testing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Drugs of Abuse Testing market
By Drug Type
By Sample Type
By Product
By Application
By End User
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Drug of Abuse Testing Market, By Drug
7.1. Drug of Abuse Testing Market, by Drug Type, 2021-2030
7.1.1. Alcohol
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Cocaine
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Marijuana/Cannabis
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. LSD
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Opioids
7.1.5.1. Market Revenue and Forecast (2019-2030)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Drug of Abuse Testing Market, By End User
8.1. Drug of Abuse Testing Market, by End User, 2021-2030
8.1.1. Workplaces
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Criminal Justice Systems
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Hospitals
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Research Labs
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Drug of Abuse Testing Market, By Sample
9.1. Drug of Abuse Testing Market, by Sample, 2021-2030
9.1.1. Urine
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Saliva
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Blood
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Drug of Abuse Testing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.3. Market Revenue and Forecast, by Sample (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.1.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Sample (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Drug (2019-2030)
10.2.7.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Sample (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Drug (2019-2030)
10.3.7.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Sample (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Drug (2019-2030)
10.4.7.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Sample (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.3. Market Revenue and Forecast, by Sample (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Sample (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Drug (2019-2030)
10.5.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Sample (2019-2030)
Chapter 11. Company Profiles
11.1. Danaher Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. LabCorp
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Quest Diagnostics, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Cordant Health Solutions
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. DrugScan
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Legacy Medical Services
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Mayo Clinic Laboratories
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. LGC Group
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Precision Diagnostics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms